Data Mining-Driven: Identification of Potential Traditional Chinese Medicine Categories Targeting Vasculogenic Mimicry in Esophageal Cancer

Yunqin Wang; Yu Wang; Qian Zhang; Ruoshui Xia; Yanqing Liu; Jue Chen

doi:10.26689/par.v9i5.12158

Yunqin Wang Affiliated Hospital of Yangzhou University, No. 368 Hanjiang Middle Road, Hanjiang District, Yangzhou 225001, Jiangsu, China
Yu Wang Affiliated Hospital of Yangzhou University, No. 368 Hanjiang Middle Road, Hanjiang District, Yangzhou 225001, Jiangsu, China
Qian Zhang Affiliated Hospital of Yangzhou University, No. 368 Hanjiang Middle Road, Hanjiang District, Yangzhou 225001, Jiangsu, China
Ruoshui Xia Affiliated Hospital of Yangzhou University, No. 368 Hanjiang Middle Road, Hanjiang District, Yangzhou 225001, Jiangsu, China
Yanqing Liu Affiliated Hospital of Yangzhou University, No. 368 Hanjiang Middle Road, Hanjiang District, Yangzhou 225001, Jiangsu, China
Jue Chen Affiliated Hospital of Yangzhou University, No. 368 Hanjiang Middle Road, Hanjiang District, Yangzhou 225001, Jiangsu, China

DOI: https://doi.org/10.26689/par.v9i5.12158

Keywords: Esophageal cancer, Vasculogenic mimicry, Recurrence and metastasis, Traditional Chinese medicine

Abstract

Background: Vasculogenic mimicry refers to a specialized tumor microvasculature independently formed by tumor cells, which facilitates the recurrence, metastasis, and therapeutic resistance in esophageal cancer. Within the framework of traditional Chinese medicine (TCM) theory, there is currently no clear conceptual classification or diagnostic-therapeutic principles for this phenomenon. Objective: To explore traditional Chinese medicine (TCM) herbs and syndrome factors related to the treatment of vasculogenic mimicry in esophageal cancer, and to provide a reference for clarifying the TCM clinical syndromes of vasculogenic mimicry in esophageal cancer. Methods: Based on public databases such as TCMSP, CNKI, and PubMed, TCM herbs related to esophageal cancer, clinical medications, and herbs inhibiting vasculogenic mimicry were retrieved. The herbs collected from multiple databases were standardized, collated, and cross-analyzed, and core herbs were screened for further analysis. Results: Among the public databases, herbs inhibiting vasculogenic mimicry and commonly used clinical herbs for esophageal cancer were mainly of the blood-activating and stasis-resolving type (Huoxue Huayu). In contrast, esophageal cancer-related herbs in the TCMSP database were mainly of the heat-clearing and toxin-resolving type (Qingre Jiedu). A total of 22 TCM herbs related to vasculogenic mimicry in esophageal cancer were identified, mainly blood-activating and stasis-resolving herbs, involving three syndrome factors: “blood stasis (Xueyu), Qi deficiency (Qixu), and Qi stagnation (Qizhi).” Conclusion: Vasculogenic mimicry can promote the progression of esophageal cancer, and blood-activating and stasis-resolving herbs may improve the prognosis of patients with esophageal cancer.

References

Yang H, Wang F, Hallemeier C, et al., 2024, Oesophageal Cancer. Lancet, 404(10466): 1991–2005.

Maniotis A, Folberg R, Hess A, et al., 1999, Vascular Channel Formation by Human Melanoma Cells in Vivo and in Vitro: Vasculogenic Mimicry. Am J Pathol, 155(3): 739–752.

Zhang Y, Wang J, Chen X, et al., 2023, Zheng Yu-ling’s Experience in Treating Advanced Esophageal Cancer with Self-prescribed Fu Gui Guanshitong Formula. Journal of Oncology in Chinese Medicine, 5(01): 28–31.

Ma H, Gao H, Wang X, et al., 2023, Study on the Rule and Safety of Blood Activating and Blood Stasis Removing Drugs in the Treatment of Malignant Tumor with Hypercoagulable State. Journal of China Prescription Drug, 21(10): 138–141.

Gao F, Guo L, Xie Y, et al., 2022, Study on Syndrome Distribution and Medication Characteristics of Patients with Rectal Cancer. Journal of Hainan Medical University, 28(23): 1810–1816 + 1828.

Du F, Yu M, Hu B, et al., 2022, Research Progress on Clinical Application and Mechanism of Chinese Medicine Pair of Sparganii Rhizoma–Curcumae Rhizoma Against Tumor. China Medical Herald, 41(5): 145–147.

Pan X, He E, Xie J, et al., 2018, Molecular Mechanism of Blood-Activating and Stasis-Removing Chinese Medicine in Regulating Blood Stasis Syndrome. Chinese Journal of Experimental Traditional Medical Formulae, 24: 227–234.

Ge Y, Xu Y, Zhu L, et al., 2021, Meta-analysis of Cinobufagin Capsules Combined with Chemotherapy in Treating Gastric Cancer. Journal of Hainan Medical University, 27(12): 902–909.

Liu J, Fang H, Yang W, et al., 2023, Advances in Antitumor Active Components and Related Mechanisms of Wenyujin (Curcuma wenyujin). Chinese Archives of Traditional Chinese Medicine, 41: 33–37.

Zhang T, Deng T, Liu Z, et al., 2023, Exploring Pan Min-qiu’s Experience in Treating Esophageal Cancer Based on the Theory of “Stasis, Toxicity, and Deficiency.” Journal of Oncology in Chinese Medicine, 5: 12–16.

Wu W, Liu X, Wu Q, 2024, Based on Zhu Danxi’s Theory of “Qi, Blood, Phlegm, and Stagnation” Four Impairments Syndrome in Exploring the Treatment of Esophageal Cancer. China’s Naturopathy, 32(9): 18–21.

Wang Y, 2016, Efficacy Observation of Chinese Herbal Medicine for Fortifying Spleen and Resolving Stasis Combined with Concurrent Chemoradiotherapy in 43 Cases of Locally Advanced Esophageal Cancer. Forum on Traditional Chinese Medicine, 31(5): 48–50.

Cui Y, Wang TM, Pan HB, 2022, Meta-analysis of Clinical Effect of the Formulas with Radix Notoginseng and Rhizoma Bletillae in the Treatment of Peptic Ulcer. China Modern Medicine, 29(23): 5–9.

Guan H, Yu C, 2024, Research Progress on Anti-tumor Mechanism of Curcumin. Chinese Archives of Traditional Chinese Medicine, 42(4): 143–151.

Liao J, Fan Z, Meng Q, et al., 2024, Research Progress on Antitumor Molecular Mechanism of Active Ingredient in Salvia Miltiorrhiza. Chinese Traditional and Herbal Drugs, 55: 6402–6415.

Gu N, Wang P, Wang Z, et al., 2023, Effect and Mechanism of Sodium Cantharidate on Proliferation, Migration and Invasion of Esophageal Cancer EC9706 Cells. Journal of Xinxiang Medical University, 40: 1114–1120 + 1125.

Zhu M, Zhou T, Liu X, et al., 2025, An Innovative Strategy for Treating Chemotherapy-Induced Immunosuppression Based on the Blood Stasis Theory. Global Traditional Chinese Medicine, 18(5): 1004–1009.

Wei T, Li Z, Gu N, et al., 2024, Professor Li Zhigang’s Clinical Experience in the Treatment of Esophageal Cancer. Chinese Journal of Integrated Traditional and Western Medicine on Digestion, 32: 440–443 + 449.

Han L, Lin X, Yan Q, et al., 2022, PBLD Inhibits Angiogenesis via Impeding VEGF/VEGFR2-Mediated Microenvironmental Cross-talk Between HCC Cells and Endothelial Cells. Oncogene, 41(13): 1851–1865.

Wechman S, Emdad L, Sarkar D, et al., 2020, Vascular Mimicry: Triggers, Molecular Interactions and In Vivo Models. Adv Cancer Res, 148: 27–67.

Andreucci E, Peppicelli S, Ruzzolini J, et al., 2022, Physicochemical Aspects of the Tumour Microenvironment as Drivers of Vasculogenic Mimicry. Cancer Metastasis Rev, 41(4): 935–951.

Yang H, Chang C, Vadivalagan C, et al., 2024, Coenzyme Q(0) Inhibited the NLRP3 Inflammasome, Metastasis/EMT, and Warburg Effect by Suppressing Hypoxia-Induced HIF-1α Expression in HNSCC Cells. Int J Biol Sci, 20(8): 2790–2813.

Zhang J, Ouyang F, Gao A, et al., 2024, ESM1 Enhances Fatty Acid Synthesis and Vascular Mimicry in Ovarian Cancer by Utilizing the PKM2-dependent Warburg Effect Within the Hypoxic Tumor Microenvironment. Mol Cancer, 23(1): 94.

Chen J, Wu S, Liao S, et al., 2024, Collateral and Stasis Generating Cancer Toxin and Malignant Tumor. China Journal of Traditional Chinese Medicine and Pharmacy, 39: 2062–2065.

Wang X, Wang Y, 2015, Discussion and Clinical Verification for Colateral Vessels, Diseases Collateral and Collateral Diseases. Journal of Beijing University of Traditional Chinese Medicine, 38(9): 581–586.

Dong L, Li Q, Zhang L, et al., 2023, State-Target Pattern Differentiation: Principles and Clinical Implementation of Herbal Formula Design. Journal of Traditional Chinese Medicine, 64: 250–254.